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Background: Infective endocarditis (IE) is a severe complication associated with high 
mortality. 
 
Objectives: To examine the clinical characteristics of IE in hemodialysis (HD) patients 
and to determine prognostic factors related to HD. 
 
Methods: From January 2008 to April 2015, 2,488 consecutive patients with definite IE 
were included. Clinical characteristics of IE patients on HD were compared with those 
of IE patients who were not on HD. 
 
Results: A total of 126 patients (63% male, median age: 66 years; IQR: 54-74 years) 
with IE (5.1%) were on HD. Fifty-two patients died during hospitalization (41%) and 17 
additional patients (14%) died during the first year. The rate of patients who 
underwent surgery during hospitalization was lower in HD patients (38 patients, 30%) 
than in non-HD patients (1,177 patients, 50%; p <0.001). Age >70 years (OR: 4.1, 95% 
CI: 1.7-10), heart failure (OR: 3.3, 95% CI: 1.4-7-6), central nervous system (CNS) 
vascular events (OR: 6.7, 95% CI: 2.1-22) and septic shock (OR: 4.1, 95% CI: 1.4-12.1) 
were independently associated with fatal outcome in HD patients. Of the 38 patients 
who underwent surgery, 15 (39.5%) died during hospitalization. 
 
Conclusions. HD patients with IE present a high mortality. Advanced age and 
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The end-stage renal disease (ESRD) population treated with hemodialysis (HD) is 
constantly increasing in western countries. Infectious endocarditis (IE) is a severe 
complication that is found progressively more frequently in these patients [1,2]. IE has 
been reported in 2-6% of HD patients [3,4], which means that the incidence of IE in this 
group is 18 to 60 times higher than in the general population [5-7]. 
 
The high prevalence of valve dysfunction and calcification, and a certain degree of 
immunosuppression related to uremia, have been proposed as elements that facilitate 
IE among patients on HD [8-10]. However, the main risk factor for developing IE in HD 
patients is the recurrent episodes of bacteremia linked with indwelling intravascular 
catheter use or arteriovenous fistula puncture [11]. IE in HD patients has been 
reported to produce a very high mortality which ranges between 29-52% [2,11-21]. 
This adverse prognosis has been linked to increased incidence of IE due Staphylococcus 
aureus and the presence of multiple comorbidities in this special population. Despite 
advances in medical and surgical therapies over the last few years [16,17,20], mortality 
has not improved significantly. 
 
The clinical characteristics of IE HD patients have not been well defined, and the 
analysis of specific prognostic risk factors in those undergoing surgery has received 
little attention [12,18,21]. Consequently, there is a need to improve knowledge 















The purpose of the present study was to outline the clinical characteristics of IE in HD 
compared to non-HD patients as well as to determine the prognostic factors of IE both 


















From January 2008 to April 2015, 3,200 consecutive patients with definite or possible 
IE, according to the modified Duke criteria [22], were prospectively included in the 
“Spanish Collaboration on Endocarditis - Grupo de Apoyo al Manejo de la Endocarditis 
infecciosa en España (GAMES)” registry maintained by 27 Spanish hospitals. 
Multidisciplinary teams completed standardized case report forms with IE episode and 
follow-up data that included clinical, microbiological and echocardiographic sections 
[23,24]. Regional and local ethics committees approved the study and all patients gave 
their informed consent. Of the 2,488 patients with definite IE included in the GAMES 




Active IE was defined as endocarditis with at least one of the following: positive blood 
cultures, fever, leukocytosis, raised inflammation markers or current antibiotic 
treatment. Microbiological diagnosis was made by blood, valve cultures and/or by 
molecular techniques [25]. Transthoracic and transesophageal echocardiography were 
performed on patients with clinical or microbiological suspicion of IE according to 
international recommendations. The same protocol was implemented for the 
diagnosis of valve dysfunction and intracardiac complications: abscess, vegetation, 
pseudoaneurysm and fistula [25,26]. The EuroScore and LogEuroScore were used to 
assess operative risk [27]. To assess comorbidity, all the necessary variables were 














defined as death, regardless of its cause, that occurred during the hospital admission 
that surgery was performed. 
 
2.2. Patients 
Data from patients with IE were analyzed, including etiology of ESRD and hemodialysis 
vintage, type of vascular access, clinical manifestations at IE presentation, the 
pathogens identified, therapy used, morbidity and mortality during hospitalization. A 
multidisciplinary team evaluated the indication for surgery taking into account, not 
only immediate surgical risk, but also the chances of long-term survival. Follow-up 
information was obtained via telephone or through written correspondence with each 
patient or their primary-care physician. The mean follow-up of IE HD patients was 3.4 
years (range, 0.3 - 6.25 years). 
 
2.3. Statistical analysis 
Quantitative variables were reported as median and interquartile range (IQR); 
qualitative variables were reported as numbers and percentages. Continuous variables 
were compared using Student’s t-test, and categorical variables were compared using 
the chi-square test or Fisher’s exact test when appropriate. Adjusted odds ratios (ORs) 
were computed using logistic regression analysis. Stepwise logistic regression analysis 
was performed which included variables present at the time of admission that 
returned a p value <0.1 in the univariate analysis but also took into consideration the 
clinical significance of each variable and the number of patients that reported the 














shown in figure 2. All statistical analyses were performed using SPSS software version 
18 (SPSS Inc., Chicago, Illinois, USA). 
3. Results 
 
A total of 126 HD patients with definite IE were included in the study (figure 1). The 
median age of patients was 66 years and 62.7% (79 patients) were male. Patients had 
been on HD for a median period of 25 months (IQR: 5 - 61 months). The etiologies of 
ESRD were diabetes mellitus (40 patients, 31.7%), glomerulonephritis (18 patients, 
14.2%), hypertension (16 patients, 12.7%), lupus nephritis (5 patients, 4%), polycystic 
disease (5 patients, 4%), myeloma/primary amyloidosis (5 patients, 4%), other causes 
(15 patients, 11.9%) and unknown (17.4%). The main characteristics of patients who 
were and were not on HD are compared in table 1. IE HD patients had diabetes, 
hypertension, immunosuppressive treatment, aortic valve infection and hospital-
acquired IE more frequently, and prosthetic valve endocarditis, atrial fibrillation, and 
perivalvular abscess less frequently. IE HD patients presented higher age-adjusted 
Charlson comorbidity index and EuroScore, and underwent surgery to a lesser extent. 
 
The type of HD vascular access in IE HD patients were permanent catheter (79 
patients, 62.7%), arteriovenous (AV) fistula (35 patients, 27.8%), temporary catheter 
(10 patients, 7.9%) and AV graft (2 patients, 1.6%). Regarding microbiology, HD 
patients presented more cases due to Staphylococcus aureus and less due to 
streptococci (table 1). Interestingly, methicillin-resistant S. aureus (MRSA) was not 














presented a higher rate of IE due to enterococci compared to patients who had a 
permanent catheter (table 2). 
 
The rate of patients who underwent surgery during hospitalization was lower in HD 
than in non-HD patients (38 patients, 30.2% vs 1,177 patients, 49.8%; p <0.001). The 
indications for surgery were heart failure (15 patients), virulent microorganism (MRSA, 
gram-negative bacilli or Candida, 12 patients), severe valve regurgitation (11 patients), 
perivalvular abscess (5 patients), persistent sepsis (3 patients), prosthetic detachment 
(1 patient), and prosthetic thrombosis (1 patient). Nine patients exhibited more than 
one indication. Surgery consisted of aortic valve replacement with mechanical (11 
patients) or bioprosthetic valve (5 patients), mitral valve replacement with mechanical 
(8 patients) or bioprosthetic valve (1 patient), repair of mitral (6 patients), aortic (3 
patients), tricuspid (3 patients) or pulmonary (1 patient) valves and pulmonary artery 
homograft (1 patient). Five patients underwent surgical removal of the hemodialysis 
catheter and 3 patients underwent surgical removal of pacemaker wires. Eight patients 
(21.1%) were submitted to more than one surgical procedure. 
 
Fifty-two patients died during hospitalization (41.3%) and 17 additional patients 
(13.5%) died during the first year after hospital discharge. Thirty-day mortality was 
higher in HD patients than in non-HD patients (p=0.003, figure 2). The leading cause of 
in-hospital death in HD patients was infection (15 patients, 28.9%), heart failure (10 
patients, 19.2%), neurological complications (10 patients, 19.2%), and multiorgan 
failure (9 patients, 17.3%). During the first year after discharge the most frequent 














patients, 23.6%) and infectious complications (3 patients, 17.6%). Mortality was not 
related to IE in 2 patients who died during hospitalization (3.8%) and in 6 patients who 
died during the following year (35.3%, p=0.002). No differences were found in in-
hospital mortality according to IE microbiology (table 3). The clinical characteristics of 
HD-patients according to patient outcome are shown in table 3. Age >70 years, age-
adjusted Charlson comorbidity index >6, septic shock, heart failure, CNS stroke and 
surgery indicated but not performed, were included in the multivariate analysis. Age 
>70 years (OR: 4.1, 95% CI: 1.7-10), heart failure (OR: 3.3, 95% CI: 1.4-7-6), CNS 
vascular events (OR: 6.7, 95% CI: 2.1-22) and septic shock (OR: 4.1, 95% CI: 1.4-12.1) 
were independently associated with fatal outcome. 
 
The in-hospital mortality in patients without surgical indication was 23.4% in HD 
patients and 11.1 % in non-HD patients (p=0.012). The mortality in patients who 
underwent surgical treatment was 39.5% in HD patients and 22.3 % in non-HD patients 
(p=0.018). In-hospital mortality was among patients with surgical indications who did 
not undergo surgery was 60%, and that of patients who underwent surgery was 39.5% 
(p=0.08). No differences in hospital stay before surgery was observed between 
survivors (21 days, IQR 12-33 days) and non-survivors (19 days, IQR: 9-27 days; 
p=0.680). The clinical characteristics related to mortality of IE patients on hemodialysis 

















The series presented here is one of the largest published to date and confirms that IE 
in HD patients constitutes a relevant group that is characterized by a distinct clinical 
and microbiological profile and high mortality. Advanced age, heart failure, CNS 
embolism and septic shock are associated with increased in-hospital mortality. Based 
on the high mortality of patients with surgical indication who did not undergo surgery, 
we believe that the proportion of patients submitted to surgery should be increased. 
This particularly applies to younger patients with a lower EuroScore and prior to the 
development of complications such as heart failure, septic shock or stroke. 
Clinical Characteristics of IE HD patients 
 
IE patients undergoing HD exhibited certain clinical characteristics that differ 
remarkably from those of non-HD IE individuals. Certain chronic diseases, such as 
diabetes, hypertension and peripheral arterial disease, were more common in HD 
patients and were related to a worse prognosis as observed in previous studies 
[11,12,18,21,29-32]. On the other hand, the low proportion of prosthetic valve IE in 
these patients may be due to repeated episodes of bacteremia being the main risk 
factor for IE in HD patients as well as the low number of HD patients who underwent 
heart valve replacement [12,21,33,34]. 
 
We found a high incidence of IE due to S. aureus and coagulase-negative staphylococci 














the vascular origin of the bacteremia [1,8,12,29,35]. Unlike other studies, a clear 
majority of IE was in HD patients undergoing dialysis via a catheter [12.36]. Higher 
incidences of methicillin resistant Staphylococcus aureus have been highlighted in 
other studies, however this was not observed in our study despite the higher rate of 
hospital acquired endocarditis [11,21,29,37]. It should also be noted that patients with 
AV fistula presented more cases due to enterococci. A high proportion of cases due to 
enterococci was similarly observed in one series comprised of patients with 
arteriovenous fistula [12]. Other studies have observed an association between IE due 
to gram-negative bacilli and use of a temporary catheter [12, 38]. The particular 
characteristics of IE in HD patients could have an impact on the prescription of 
empirical treatment in this group. Based on our results, we believe that etiological 
peculiarities of IE in HD patients and the type of vascular access and local epidemiology 
are factors that should be considered when selecting antimicrobial therapy. In our 
study, the type of microorganism causing IE did not influence mortality, which is 
consonant with previous series, but may be noteworthy taking into account the higher 
mortality classically associated with S. aureus IE [15,18,36,39,40]. 
 
Outcomes of IE in HD 
 
We found a very high in-hospital mortality among IE HD patients. Comorbidities, 
disturbances of hemodynamic, metabolic and immunological functions associated to 
ESRD and the high incidence of virulent microorganisms may partially explain the 
increased mortality found in these individuals [16,11,13,14,26,30,33,39,41,42,43]. 














considering the lower rates of fever, the possibly lower sensitivity of echocardiography 
and the unfeasibility of urinalysis in this setting [16,43,44]. Our in-hospital mortality 
was 41.3% and the accumulated mortality during the first year was 54.8%. Although 
mortality was lower in other previously reported IE HD series (around 25%) 
[11,17,19,22,36], comparable or even higher mortality has also been described 
[12,13,30,33]. The heterogeneity of reported series with relevant differences regarding 
clinical setting, patient age and rate of chronic diseases, valve disease, congestive 
heart failure, septic shock, perioperative surgical complications and criteria for 
mortality could justify these differences in mortality 
[9,12,13,16,18,19,21,29,30,33,34,41,45,46]. Nevertheless our study reports a national-
based cohort, which might better reflect the “real” mortality in this fragile patient 
population. Compared to other IE HD series, our patients showed advanced age, and 
all those that underwent surgery did so during the same hospital admission, therefore 
in the period of active IE, which might suggest greater severity of the disease [18,21]. 
Patient's age and the presentation of heart failure, CNS vascular events and septic 
shock were independently associated with fatal outcome. The most significant 
prognostic factor of IE in HD patients related to in-hospital mortality described in 
previous studies were older age [18,29], health care environment acquisition [29], 
active endocarditis [21], double valve endocarditis [29,31], staphylococcal etiology 
[18,29] methicillin-resistant Staphylococcus aureus [50] cardiogenic shock [21], stroke 
[29] and septic embolism [39]. Despite not reaching statistical significance, diabetic 
patients presented higher mortality than other groups (table 3). Abnormalities in 
neutrophil chemotaxis, adhesion and intracellular killing may be associated to the 















Another remarkable finding in our study is the low rate of patients who underwent 
surgery in comparison with the non-HD IE population. According to several studies, the 
rate of surgery varies from to 8%-50% in theses patients [12,16,18,19,30,33,36,39]. In 
our series, only half of the patients in whom surgery was indicated finally underwent 
this procedure. Since no randomized controlled have been performed to compare 
medical versus surgical treatment in these patients, certain doubts remain about 
whether accepted indications for valve replacement in the general population are 
applicable to HD patients [1]. In any case, mortality in patients with surgical indications 
that did not undergo surgery, which was around 60%, was remarkably high. Although 
the mortality in these patients is high whether or not they undergo surgery, we 
consider that it is essential to identify those patients who could benefit most from 
surgical treatment [21]. 
 
Outcome in IE HD patients who underwent surgery 
 
Given the modest results of cardiac surgery in IE HD, the identification of factors 
associated with poor outcomes during surgery is highly warranted. Finally, we did not 
perform a multivariate analysis because of the low number of patients who underwent 
surgery, thereby limiting their discriminative capacity. Among the variables associated 
with mortality in the univariate analysis were age over 70 years and a high EuroScore 
[27]. Advanced age has been considered an independent predictor of mortality for IE 
in HD patients, both in patients who undergo surgery and in those treated medically 














age and several clinical characteristics, such as active endocarditis and double valve 
endocarditis, which may be useful to identify patients with excessive surgical risk, 
however, HD was not among the clinical factors which indicated surgery as having a 
higher risk [21]. Another study found that older age, diabetes mellitus, staphylococcal 
IE causative, arrhythmia and surgery during index hospitalization were independent 
predictors of high mortality in patients undergoing valve replacement due to IE [18]. 
 
Selecting patients who would benefit more from surgery is a delicate task that requires 
careful analysis by a multidisciplinary IE team, as is usually performed in our hospitals. 
CNS embolism has been reported as a poor prognostic factor in HD patients [17,34,41]. 
Some of our patients did not undergo surgery solely because they had suffered a 
stroke, which is associated with a poor prognosis. Therefore, in our study, CNS embolic 
complications emerged as important prognostic factor. In this regard, it should be 
noted that, according to several studies containing a small subgroup of HD patients, 
ischemic stroke does not seem to increase mortality in IE patients undergoing urgent 
surgery [50,51]. Finally, we agree with Horstkotte and Piper in that, once surgical 
treatment has been decided on, it would be desirable carry out this procedure as soon 
as possible before additional complications, such as stroke, appear [52]. 
 
Other possible matters to consider in order to reduce patient mortality may be to take 
advantage of thrice-weekly contacts with an HD physician for better clinical 
monitoring, to switch the patient from HD to peritoneal dialysis, to improve knowledge 
of the pharmacokinetics and pharmacodynamics of antibiotics in these patients, and to 














accurate guidelines for selecting those patients who may benefit most from surgery is 
still pending. A controlled trial comparing medical versus surgical therapy would 




Some limitations of the study should be noted. The first is that this was an 
observational study and comparisons may be biased by different patient 
characteristics in each group. In addition, most of the institutions participating in the 
GAMES registry are tertiary university hospitals that receive a substantial number of 
patients from other centers (most of which do not have facilities for cardiac surgery), 
which could represent a selection bias. Another limitation is that a possible cluster 
effect was not studied. However, we did not expect enough heterogeneity between 
centers to influence our results significantly. Furthermore, the number of HD patients 
who underwent surgery is low and could therefore have prevented the detection of 
other prognostic factors associated with mortality in those patients who did undergo 
cardiac surgery. As in other studies, a high proportion of IE HD patients did not 
undergo surgery, consequently a significant selection bias cannot be ruled out. 
Another limitation is that knowledge about the risk of IE according to vascular access 

















This study describes the clinical profile of IE HD and identifies several factors 
associated to in-hospital mortality in these patients and in those who undergo surgery. 
According to our results, advanced age and certain IE complications are associated 
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Figure 2. 30-day mortality according to hemodialysis in a cohort of definite 

























Age (years) 66 (54 - 74) 68 (56 - 77) 0.143 
Male gender 79 (62.7) 1621 (68.8) 0.153 
Diabetes mellitus 56 (44.8) 625 (26.5) <0.01 
Hypertension 107 (84.9) 1251 (53.1) <0.01 
Peripheral arterial disease 43 (34.7) 227 (9.6) <0.01 
Cerebrovascular disease 19 (15.1) 298 (12.6) 0.308 
Immunosuppressive treatment 21 (16.7) 125 (5.3) <0.01 
Neoplasia 12 (9.5) 364 (15.4) 0.184 
Atrial fibrillation 18 (4.3) 603 (25.6) 0.017 
Site of infection   0.096 
Mitral 52 (41.3) 1189 (50.3)   
Aortic 57 (45.2) 1074 (45.5)   
Implanted heart device 20 (15.9) 256 (10.8)   
Prosthetic IE 11 (8.7) 728 (30.8)    
Microbiology    
Gram-positive bacteria    
Coagulase-negative 
staphylococci  
28 (22.2) 419 (17.7) 0.202 















    MRSA 6 (4.7) 89 (3.7) 0.742 
Enterococcus spp 18 (14.3) 344 (14.6) 0.931 
Streptococcus spp 
7 (5.6) 670 (28.4) 
<0.00
1 
Gram-negative bacilli 5 (4.0) 92 (3.9) 0.968 
Anaerobic bacteria 0 26 (1.1) 0.236 
Fungi    
Candida spp 3 (2.4) 37 (1.6) 0.479 
Other fungi 0 10 (0.4) 0.464 
Polymicrobial  2 (1.6) 48 (2.0) 0.729 
Other microorganisms 2 (2.7) 72 (3.0) 0.347 
Negative cultures  5 (4.0) 92 (3.9) 0.968 
Fever 107 (88.4) 1980 (84.5) 0.275 
Septic shock 23 (18.4) 278 (11.8) 0.086 
Persistent bacteremia 16 (12.7) 275 (11.7) 0.204 
CNS vascular events 19 (15.1) 490 (20.8) 0.060 
Non-neurologic embolisms 32 (25.4) 537 (22.7) 0.501 
Heart failure 49 (38.9) 986 (41.9) 0.470 
C-reactive protein (mg/dl) 28.5 (11 - 122) 25 (9 - 91) 0.148 
Echocardiographic findings    
Vegetation 8 (85.7) 1839 (77.9) 0.037 














Valve perforation or rupture 23 (18.2) 335 (14.1) 0.255 
Pseudoaneurysm 7 (5.5) 134 (5.6) 0.887 
Intracardiac fistula 1 (0.8) 71 (3.0) 0.241 
Surgical indication 73 (57.9) 1647 (70.1) 0.009 
Surgery performed 38 (30.2) 1177 (49.8) <0.00
1 
Surgery indicated (but  not 
performed) 35 (47.9) 470 (28.5) 
<0.00
1 
EuroScore (points) 12 (9 - 16) 10 (7 - 14) <0.00
1 
Hospital stay median (days) 42 (27 - 60) 26 (11 - 40) <0.00
1 
In-hospital mortality 52 (41.3) 624 (26.4) <0.00
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7 (20.0) 20 (22.5) 0.809 
S. aureus 11 (31.4) 43 (48.3) 0.106 
    MRSA 0 6 (6.7) 0.182 
Enterococcus spp 9 (25.7) 9 (10.1) 0.027 
Streptococcus spp 4 (11.4) 3 (3.4) 0.097 
Other microorganisms 4 (2.9) 8 (9) 0.738 
Negative cultures (no 
growth) 
0 6 (6.7) 0.182 
 
1 79 patients had permanent catheters and 10 patients temporary catheters. Two IE HD 
patients had arteriovenous grafts. 
 
























Age (years) 62 (51 - 73) 71 (59 - 75) 0.036 
Male gender 50 (67.6) 29 (55.8) 0.178 
Diabetes mellitus 28 (37.8) 28 (53.8) 0.086 
Hypertension 62 (83.8) 45 (86.5) 0.383 
Peripheral arterial disease 26 (35.1) 17 (32.7) 0.793 
Cerebrovascular disease 8 (10.8) 11 (21.2) 0.126 
Immunosuppressive 
treatment 
10 (13.5) 11 (21.2) 0.243 




1 (0.75-1.25) 2 (0.5-3) 0.016 
Previous IE episode 5 (6.8) 2 (3.8) 0.483 
Hospital-acquired 
infection 
28 (37.8) 20 (38.4) 0.876 
Time on hemodialysis 
(months) 
31 (4 - 73) 21 (6 - 48) 0.530 
Type of vascular access     














AV fistulae 22 (29.7) 15 (28.8) 0.920 
AV graft 1 (1.4) 1 (1.9) 1 
Transferred from other 
hospitals 
17 (23.0) 11 (21.2) 0.809 
Site of infection   0.451 
Mitral 29 (39.2) 28 (53.8)   
Aortic 31 (41.9) 21 (40.4)   
Tricuspid 9 (12.1) 3 (5.8)   
Pulmonary 1 (1.6) 1 (1.9)   
Native valve 58 (78.4) 48 (92.3) 0.035 
Prosthetic valve 8 (10.8) 3 (5.8) 0.324 
Implanted heart device 13 (17.6) 7 (13.5) 0.535 
Microbiology    
Gram-positive 
bacteria 
   
Coagulase-negative 
staphylococci 14 (18.9) 14 (26.9) 0.287 
S. aureus 32 (43.2) 23 (44.2) 0.912 
    MRSA 3 (10) 3 (13) 0.594 
Enterococcus spp 12 (16.2) 6 (11.5) 0.460 
Streptococcus spp 5 (6.8) 2 (3.8) 0.483 
Gram-negative bacilli 3 (4.1) 2 (3.8) 0.953 














Polymicrobial  2 (2.7) 0 0.232 
Other 
microorganisms 1 (1.4) 1 (1.9) 0.800 
Negative cultures  3 (4.1) 3 (5.8) 0.656 
Septic shock 9 (12.2) 14 (26.9) 0.041 
Heart failure 22 (29.7) 27 (51.9) 0.012 
Persistent bacteremia 5 (6.8) 11 (21.2) 0.017 
CNS vascular events 5 (6.8) 14 (26.9) 0.017 
Non-neurologic 
embolisms 
32 (25.4) 12 (23.1) 0.501 
C reactive protein (mg/dl) 31 (8 - 125) 28 (18 - 117) 0.431 
Echocardiographic 
findings 
   
Vascular graft 
vegetations 
   
Perivalvular abscess 5 (6.7) 6 (11.5) 0.538 
Valve perforation or 
rupture 
13 (17.5) 10 (19.2) 0.997 
Pseudoaneurysm 3 (4.0) 4 (7.7) 0.625 
EuroScore (points) 11 (7 - 13) 15 (12 - 18) <0.01 
Surgical indication 37 (50) 36 (69.2) 0.010 
Surgery performed 23 (31.1) 15 (28.8) 0.788 















Emerging surgery 2 (8.7) 1 (6.7) 0.760 
 
1 Mortality during hospitalization. Quantitative variables are reported with median and 






























Age (years) 62 (54 - 69) 71 (63 - 80) 0.017 
Male gender 18 (78.3) 8 (53.3) 0.106 
Diabetes mellitus 8 (34.8) 8 (53.3) 0.258 
Atrial fibrillation 1 (4.3) 4 (26.7) 0.047 
Peripheral arterial disease 6 (26.1) 4 (28.6) 0.869 
Age-adjusted Charlson Comorbidity Index 
(points) 
5 (2-7) 6 (2-8) 0.073 
Hospital-acquired infection 12 (52.2) 6 (40.0) 0.463 
Transferred from other hospital 9 (39.1) 4 (26.7) 0.429 
Site of infection   0.189 
Aortic 15 (65.2) 6 (40.0)  
MItral 5 (21.7) 7 (46.7)  
Vegetation  80 (87.0) 14 (93.3) 0.531 
Vegetation size (mm) 12 (5-8) 12 (5-7) 0.458 
Septic shock 1 (4.3) 2 (13.3) 0.315 
Heart failure 12 (52.2) 7 (46.7) 0.740 
Persistent bacteremia 0 4 (26.7) 0.009 














EuroScore (points) 9.9 (4.3) 20 (18.3) <0.01 
Time until surgery (days) 21 (12 - 33) 19 (9 - 27) 0.680 
Mitral mechanical valve replacement 2 (8.7) 6 (40) 0.039 
Aortic mechanical valve replacement 9 (39.1) 1 (6.7) 0.026 
 
Quantitative variables are reported with median and interquartile range 
